{"schema_version":"secwatch.filing_event.v1","accession":"0001698530-26-000060","form_type":"8-K","ticker":"XCUR","cik":"0001698530","company_name":"EXICURE, INC.","filed_at":"2026-06-01T19:30:08+00:00","discovered_at":"2026-06-01T19:31:00.560543+00:00","generated_at":"2026-06-01T19:31:14.469906+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Exicure gets Nasdaq delinquency notice for late 10-Q; files next day, says compliance regained","bullets":["Received Nasdaq delinquency notice on May 28, 2026 for late Q1 2026 10-Q filing.","Delayed due to changes in financial reporting personnel and related procedures.","Filed the delinquent 10-Q on May 29, 2026, one day after the notice.","Believes it has regained compliance with Nasdaq Listing Rule 5250(c)(1)."],"urls":{"canonical":"https://secwatch.observer/filing/0001698530-26-000060","json":"https://secwatch.observer/filing/0001698530-26-000060.json","markdown":"https://secwatch.observer/filing/0001698530-26-000060.md","text":"https://secwatch.observer/filing/0001698530-26-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1698530/000169853026000060/0001698530-26-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1698530/000169853026000060/xcur-20260601.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T19:31:14.469906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001213900-26-054956","ticker":"MSS","company_name":"Maison Solutions Inc.","filed_at":"2026-05-12T17:22:23+00:00","headline":"Maison Solutions regains Nasdaq minimum bid price compliance; listing continues","event_type":"regulatory","sec_items":["7.01","8.01","9.01"],"materiality_score":0.2,"calibrated_materiality_score":0.2,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054956","json":"https://secwatch.observer/filing/0001213900-26-054956.json","markdown":"https://secwatch.observer/filing/0001213900-26-054956.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1892292/000121390026054956/0001213900-26-054956-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1892292/000121390026054956/ea0290261-8k_maison.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-067517","ticker":"CLIR","company_name":"ClearSign Technologies Corp","filed_at":"2026-05-28T20:19:02+00:00","headline":"ClearSign Technologies suspends ATM prospectus supplement for $10.39 million common stock offering; no shares sold","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same SEC item: 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-067517","json":"https://secwatch.observer/filing/0001104659-26-067517.json","markdown":"https://secwatch.observer/filing/0001104659-26-067517.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434524/000110465926067517/0001104659-26-067517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434524/000110465926067517/tm2615697d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-025087","ticker":"LASE","company_name":"Laser Photonics Corp","filed_at":"2026-05-22T21:27:31+00:00","headline":"Laser Photonics receives Nasdaq delisting notice for late Q1 2026 10-Q","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same SEC item: 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025087","json":"https://secwatch.observer/filing/0001493152-26-025087.json","markdown":"https://secwatch.observer/filing/0001493152-26-025087.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807887/000149315226025087/0001493152-26-025087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807887/000149315226025087/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001665988-26-000029","ticker":"BVS","company_name":"Bioventus Inc.","filed_at":"2026-05-21T20:58:18+00:00","headline":"Bioventus Exogen device reclassified by FDA, CMS updates reimbursement rates; company reiterates 2026 guidance","event_type":"regulatory","sec_items":["7.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same SEC item: 7.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001665988-26-000029","json":"https://secwatch.observer/filing/0001665988-26-000029.json","markdown":"https://secwatch.observer/filing/0001665988-26-000029.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000029/0001665988-26-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000029/bvs-20260521.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-056656","ticker":"AIRE","company_name":"reAlpha Tech Corp.","filed_at":"2026-05-14T20:20:34+00:00","headline":"reAlpha regains Nasdaq minimum bid price compliance; matter closed","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same SEC item: 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-056656","json":"https://secwatch.observer/filing/0001213900-26-056656.json","markdown":"https://secwatch.observer/filing/0001213900-26-056656.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859199/000121390026056656/0001213900-26-056656-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859199/000121390026056656/ea0290935-8k_realpha.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":null},{"accession":"0001140361-26-023560","ticker":"NJR","company_name":"NEW JERSEY RESOURCES CORP","filed_at":"2026-06-01T20:03:21+00:00","headline":"NJNG files base rate case seeking $157.6M increase; offers 8.9% winter bill cut","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023560","json":"https://secwatch.observer/filing/0001140361-26-023560.json","markdown":"https://secwatch.observer/filing/0001140361-26-023560.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/356309/000114036126023560/0001140361-26-023560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/356309/000114036126023560/ef20075084_8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026519","ticker":"ELTP","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2026-06-01T11:00:24+00:00","headline":"Elite Pharmaceuticals files ANDA for generic anticoagulant; $26B brand market, no generic available","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026519","json":"https://secwatch.observer/filing/0001493152-26-026519.json","markdown":"https://secwatch.observer/filing/0001493152-26-026519.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226026519/0001493152-26-026519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226026519/form8-k.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}